532934-93-3

Usage

Uses

Used in Pharmaceutical Industry:
4-IODO-2-METHYL-6-NITROBENZENAMINE is used as an intermediate in the synthesis of pharmaceuticals for its unique properties and reactivity. Its presence of iodo and nitro groups allows for the development of new drugs with potential therapeutic benefits.
Used in Dye Industry:
4-IODO-2-METHYL-6-NITROBENZENAMINE is used as a precursor in the production of dyes due to its ability to impart color and its chemical structure that can be modified to create a range of hues.
Used in Agrochemical Industry:
4-IODO-2-METHYL-6-NITROBENZENAMINE is used as a building block in the development of agrochemicals, such as pesticides and herbicides, where its chemical properties can be leveraged to create effective and targeted products for agricultural use.

InChI:InChI=1/C7H7IN2O2/c1-4-2-5(8)3-6(7(4)9)10(11)12/h2-3H,9H2,1H3

Upstream product

• 570-24-1 2-Methyl-6-nitroaniline 
• 7790-99-0 Iodine monochloride 
• 64-19-7 acetic acid 

Downstream Products

• 936939-22-9 (4-amino-3-methyl-5-nitro-phenyl)-difluoro-acetic acid ethyl ester 
• 860751-92-4 2,5-diiodo-3-methylaniline 
• 866996-39-6 2,5-diiodo-3-nitrotoluene 
• 1643440-50-9 4-methyl-3,6-bis(o-tolyl)-1,2-benzenedisulfonimide 
• 1643440-45-2 5-methyl-2-(3-methylbutoxy)-4,7-bis(o-tolyl)-1,3-benzodithiole 
• 1643440-43-0 6-methyl-4,7-bis(o-tolyl)isatin 
• 1643440-41-8 N-(2,5-diiodo-3-methylphenyl)(hydroxyimino)acetamide 
• 532934-96-6 6-iodo-8-methylquinoxaline 
• 880762-08-3 1-(4-amino-3-methyl-5-nitrophenyl)pyridin-2(1H)-one 
• 936939-29-6 4-(8-benzyl-2,8-diaza-spiro[5.5]undec-2-yl)-2-methyl-6-nitro-phenylamine 
• 936939-28-5 4-(7-ethyl-2,7-diaza-spiro[4.4]non-2-yl)-2-methyl-6-nitro-phenylamine 

Relevant academic research and scientific papers

Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N and E138K Mutants and Pharmacokinetic Profiles

Molecular hybridization is a powerful strategy in drug discovery. A series of novel diarylbenzopyrimidine (DABP) analogues were developed by the hybridization of FDA-approved drugs etravirine (ETR) and efavirenz (EFV) as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs). Substituent modifications resulted in the identification of new DABPs with the combination of the strengths of the two drugs, especially compound 12d, which showed promising activity toward the EFV-resistant K103N mutant. 12d also had a favorable pharmacokinetic (PK) profile with liver microsome clearances of 14.4 μL/min/mg (human) and 33.2 μL/min/mg (rat) and an oral bioavailability of 15.5% in rat. However, its activity against the E138K mutant was still unsatisfactory; E138K is the most prevalent NNRTI resistance-associated mutant in ETR treatment. Further optimizations resulted in a highly potent compound (12z) with no substituents on the phenyl ring and a 2-methyl-6-nitro substitution pattern on the 4-cyanovinyl-2,6-disubstitued phenyl motif. The antiviral activity of this compound was much higher than those of ETR and EFV against the WT, E138K, and K103N variants (EC50 = 3.4, 4.3, and 3.6 nM, respectively), and the cytotoxicity was decreased while the selectivity index (SI) was increased. In particular, this compound exhibited acceptable intrinsic liver microsome stability (human, 34.5 μL/min/mg; rat, 33.2 μL/min/mg) and maintained the good PK profile of its parent compound EFV and showed an oral bioavailability of 16.5% in rat. Molecular docking and structure-activity relationship (SAR) analysis provided further insights into the binding of the DABPs with HIV-1 reverse transcriptase and provided a deeper understanding of the key structural features responsible for their interactions.

Chiral derivatives of 1,2-benzenedisulfonimide as efficient Bronsted acid catalysts in the Strecker reaction

Two chiral derivatives of 1,2-benzenedisulfonimide, namely 4-methyl-3,6-bis(o-tolyl)-1,2-benzenedisulfonimide and 4,5-dimethyl-3,6-bis(o- tolyl)-1,2-benzenedisulfonimide, have been easily synthesized in good overall yields (respectively 34% and 41%) by me

The nitration of 8-methylquinoxalines in mixed acid

8-Methylquinoxalines are nitrated surprisingly efficiently at C-5 following a simple nitration protocol with mixed acid at 40-50°C. The implications of halogen functionalisation at C-6 and modification of the mixed acid conditions on the relative rates of conversion and process safety are discussed. Competing side reactions for 6-halo-8-methylquinoxalines involve hydrolysis at C-6 and halogenation at C-7 or C-5.